modified FOLFIRINOX (mFOLFIRINOX)

DRUG2 trials

Sponsors

BioNTech Research & Development, Inc., Dartmouth-Hitchcock Medical Center

Conditions

Pancreas AdenocarcinomaPancreatic Cancer

Phase 1

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

TerminatedNCT02672917

BioNTech Research & Development, Inc.Pancreatic Cancer

Start: 2016-01-31End: 2025-01-14Updated: 2025-01-28

Phase 2

24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

RecruitingNCT07043270

Dartmouth-Hitchcock Medical CenterPancreas Adenocarcinoma

Start: 2025-09-29End: 2029-07-01Target: 35Updated: 2025-10-20

Related Papers

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.

Journal of Clinical Oncology2024-01-201 citations

HuMab-5B1 (MVT-5873), a mAb targeting sLe<sup>a</sup>, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

Journal of Clinical Oncology2018-05-206 citations

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe<sup>a</sup>, in patients with pancreatic cancer and other CA19-9 positive malignancies.

Journal of Clinical Oncology2017-05-204 citations

Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model

Cancer Research2016-12-144 citations